Amgen Inc. (AMGN)
|52 Week Range||214.48-296.67|
|1y Target Est||-|
|DCF Unlevered||AMGN DCF ->|
|DCF Levered||AMGN LDCF ->|
|Debt / Equity||1558.94%||Strong Buy|
Upgrades & Downgrades
Latest AMGN news
Amgen: Appeal Becomes Visible Despite Uncertainty On The 'Horizon'
29 May 2023
Amgen's stock has seen a further pullback since it announced an acquisition of Horizon Therapeutics in December. Shares are down by nearly a quarter as the re-rating starts to look interesting with fu...
AMGEN TO PRESENT AT THE TD COWEN 4TH ANNUAL ONCOLOGY INNOVATION SUMMIT
26 May 2023
THOUSAND OAKS, Calif. , May 26, 2023 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the TD Cowen 4th Annual Oncology Innovation Summit at 11:00 a.m.
Is the Options Market Predicting a Spike in Amgen (AMGN) Stock?
26 May 2023
Investors need to pay close attention to Amgen (AMGN) stock based on the movements in the options market lately.
Best Retirement Stocks to Buy Now
25 May 2023
The best retirement stocks ideally have high dividend yields that can be sustained. This can lead to steady income and long-term value for retirees.
3 Dogs of the Dow for High-Yield Investors
25 May 2023
The “Dogs of the Dow” strategy consists of investing in the 10 highest-yielding stocks in the Dow Jones Industrial Average. Purchasing the Dogs of the Dow creates higher dividend income by focusing on...
Elizabeth Warren and the FTC Are the Least of Amgen's Problems
24 May 2023
The biotech company is facing a patent cliff scarier than Washington's actions.
FTC Wants to Block the Amgen-Horizon Deal: Is Pfizer's Acquisition of Seagen at Risk, Too?
24 May 2023
There isn't much overlap between Amgen's business and Horizons', but that isn't stopping the FTC from looking to block the deal. Pfizer has a strong oncology portfolio and is planning to acquire Seage...
US judge hearing fight over Amgen deal for Horizon eyes September trial
23 May 2023
The judge who will decide if Amgen can go forward with its $27.8 billion purchase of Horizon Therapeutics on Tuesday said he was considering an evidentiary hearing on the matter in September.
Amgen settles J&J patent lawsuit over drug similar to blockbuster Stelara
23 May 2023
Johnson & Johnson's Janssen Biotech Inc has settled its lawsuit against Amgen Inc over Amgen's proposed similar version of J&J's top-selling drug Stelara, according to a filing Monday in Delaware fede...
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >